Bicycle Therapeutics (BCYC) Competitors $8.00 -0.23 (-2.79%) Closing price 04:00 PM EasternExtended Trading$7.98 -0.02 (-0.25%) As of 04:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BCYC vs. RXRX, DNLI, MESO, ANIP, ADPT, DYN, VERA, SRPT, APGE, and NTLAShould you be buying Bicycle Therapeutics stock or one of its competitors? The main competitors of Bicycle Therapeutics include Recursion Pharmaceuticals (RXRX), Denali Therapeutics (DNLI), Mesoblast (MESO), ANI Pharmaceuticals (ANIP), Adaptive Biotechnologies (ADPT), Dyne Therapeutics (DYN), Vera Therapeutics (VERA), Sarepta Therapeutics (SRPT), Apogee Therapeutics (APGE), and Intellia Therapeutics (NTLA). These companies are all part of the "pharmaceutical products" industry. Bicycle Therapeutics vs. Its Competitors Recursion Pharmaceuticals Denali Therapeutics Mesoblast ANI Pharmaceuticals Adaptive Biotechnologies Dyne Therapeutics Vera Therapeutics Sarepta Therapeutics Apogee Therapeutics Intellia Therapeutics Recursion Pharmaceuticals (NASDAQ:RXRX) and Bicycle Therapeutics (NASDAQ:BCYC) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation. Is RXRX or BCYC more profitable? Recursion Pharmaceuticals has a net margin of -1,004.91% compared to Bicycle Therapeutics' net margin of -1,257.00%. Bicycle Therapeutics' return on equity of -32.43% beat Recursion Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Recursion Pharmaceuticals-1,004.91% -76.09% -54.29% Bicycle Therapeutics -1,257.00%-32.43%-26.80% Which has stronger earnings and valuation, RXRX or BCYC? Bicycle Therapeutics has lower revenue, but higher earnings than Recursion Pharmaceuticals. Recursion Pharmaceuticals is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRecursion Pharmaceuticals$58.84M38.59-$463.66M-$1.78-2.94Bicycle Therapeutics$19.28M28.76-$169.03M-$3.51-2.28 Does the media favor RXRX or BCYC? In the previous week, Bicycle Therapeutics had 11 more articles in the media than Recursion Pharmaceuticals. MarketBeat recorded 13 mentions for Bicycle Therapeutics and 2 mentions for Recursion Pharmaceuticals. Recursion Pharmaceuticals' average media sentiment score of 0.94 beat Bicycle Therapeutics' score of -0.04 indicating that Recursion Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Recursion Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bicycle Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility & risk, RXRX or BCYC? Recursion Pharmaceuticals has a beta of 0.91, indicating that its stock price is 9% less volatile than the S&P 500. Comparatively, Bicycle Therapeutics has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500. Do analysts rate RXRX or BCYC? Recursion Pharmaceuticals currently has a consensus price target of $7.25, indicating a potential upside of 38.62%. Bicycle Therapeutics has a consensus price target of $22.22, indicating a potential upside of 177.78%. Given Bicycle Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Bicycle Therapeutics is more favorable than Recursion Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Recursion Pharmaceuticals 1 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17Bicycle Therapeutics 1 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.50 Do institutionals and insiders believe in RXRX or BCYC? 89.1% of Recursion Pharmaceuticals shares are held by institutional investors. Comparatively, 86.2% of Bicycle Therapeutics shares are held by institutional investors. 8.4% of Recursion Pharmaceuticals shares are held by insiders. Comparatively, 22.9% of Bicycle Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryBicycle Therapeutics beats Recursion Pharmaceuticals on 10 of the 16 factors compared between the two stocks. Get Bicycle Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCYC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BCYC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCYC vs. The Competition Export to ExcelMetricBicycle TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$554.46M$3.32B$6.10B$10.53BDividend YieldN/A2.29%5.51%4.67%P/E Ratio-2.2821.5485.6826.86Price / Sales28.76422.92582.47185.05Price / CashN/A46.3226.3031.10Price / Book0.7010.0613.246.72Net Income-$169.03M-$52.22M$3.30B$276.35M7 Day Performance3.36%5.85%4.67%3.10%1 Month Performance11.73%12.06%8.40%10.19%1 Year Performance-65.81%26.14%88.01%40.34% Bicycle Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCYCBicycle Therapeutics4.0241 of 5 stars$8.00-2.8%$22.22+177.8%-65.1%$554.46M$19.28M-2.28240Trending NewsGap UpRXRXRecursion Pharmaceuticals2.4604 of 5 stars$4.91+4.0%$7.25+47.7%-9.5%$2.05B$58.84M-2.76400DNLIDenali Therapeutics4.2443 of 5 stars$14.52+4.1%$33.50+130.7%-46.8%$2.04B$330.53M-5.19430MESOMesoblast2.0843 of 5 stars$16.02+1.0%$24.00+49.8%+60.2%$2.03B$17.20M0.0080News CoverageGap UpANIPANI Pharmaceuticals3.6206 of 5 stars$91.93-1.2%$97.29+5.8%+59.2%$2.02B$614.38M-119.39600ADPTAdaptive Biotechnologies3.0203 of 5 stars$13.46+1.8%$12.38-8.1%+162.1%$2.01B$178.96M-16.41790DYNDyne Therapeutics3.5737 of 5 stars$12.37-5.9%$34.07+175.4%-61.2%$1.87BN/A-3.20100News CoverageVERAVera Therapeutics2.7838 of 5 stars$28.90+2.5%$63.00+118.0%-24.2%$1.80BN/A-8.0740Positive NewsSRPTSarepta Therapeutics4.6409 of 5 stars$18.82+2.5%$39.32+108.9%-80.7%$1.79B$1.90B-21.631,372APGEApogee Therapeutics3.1171 of 5 stars$39.83+4.2%$92.63+132.6%-26.9%$1.76BN/A-9.6491NTLAIntellia Therapeutics4.5238 of 5 stars$16.92+3.7%$27.39+61.9%+14.2%$1.75B$57.88M-3.61600Trending NewsAnalyst Upgrade Related Companies and Tools Related Companies Recursion Pharmaceuticals Competitors Denali Therapeutics Competitors Mesoblast Competitors ANI Pharmaceuticals Competitors Adaptive Biotechnologies Competitors Dyne Therapeutics Competitors Vera Therapeutics Competitors Sarepta Therapeutics Competitors Apogee Therapeutics Competitors Intellia Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCYC) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicycle Therapeutics PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Bicycle Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
